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Replicative fitness of historical and recent HIV-1
isolates suggests HIV-1 attenuation over time
Kevin K. Arie¨na, Ryan M. Troyerb, Youssef Galia,
Robert L. Colebundersc, Eric J. Artsb and Guido Vanhama,d
Background: Changes in virulence during an epidemic are common among pathogens,
but still unexplored in the case of HIV-1. Here we used primary human cells to study
the replicative fitness of primary HIV-1 isolates from untreated patients, comparing
historical (1986–1989) and recent samples (2002–2003).
Methods: Head-to-head dual virus infection/competition assays were performed in
both peripheral blood mononuclear cells and human dendritic cell/T-cell co-cultures
with pairs of 12 carefully matched historical and recent HIV-1 isolates from untreated
patients. Sensitivity to inhibition by lamivudine (3TC) and TAK-779 of historical and
recent R5 HIV-1 isolates was measured in a subset of samples.
Results: Overall, the historical HIV-1 out-competed the recent HIV-1 isolates in 176 of
238 competitions and in 9 of 12 competitions carefully matched for CD4 cell count. The
mean relative replicative fitness (W) of all historical HIV-1 strains was significantly
greater than that of recent HIV-1 isolates (W1986–1989 ¼ 1.395 andW2002–2003 ¼ 0.545,
P < 0.001 (t test)). The more fit viruses (mean W > 1) from 1986–1989 appeared less
sensitive to TAK-779 and 3TC than did the less fit (mean W < 1) 2002–2003 viruses.
Conclusions: These findings suggest that HIV-1 replicative fitness may have decreased
in the human population since the start of the pandemic. This ‘attenuation’ could be the
consequence of serial bottlenecks during transmission and result in adaptation of HIV-1
to the human host.  2005 Lippincott Williams & Wilkins
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Introduction
Zoonotic jumps from SIV-infected chimpanzees and
sooty mangabeys are the likely origin of HIV-1 and HIV-
2 (respectively) in humans [1]. HIV-2 appears less
pathogenic than HIV-1 [2,3] and, although some rare
cases of infections with defective HIV-1 have been
documented [4–6], the vast majority of HIV-1 infections
results in lethal immunodeficiency disease in man. Within
the simian hosts, infection with these native SIVs do not
manifest into severe clinical symptoms whereas experi-
mental transfers of SIV into non-native simian hosts (such
as macaques) usually results in a rapid and fatal outcome
[7,8].
Molecular adaptation and continuous selection may
influence HIV virulence in the human population [9,10].
Although current theories suggest that HIV-1 replicative
fitness and genetic diversity increases during disease
progression [11–13] in the face of host immune pressure,
the stringent genetic bottlenecks upon transmission may
in effect reset the fitness to a lower set-point in each new
host. As with decreasing virulence with other lethal
pathogens in a host population [14], HIV-1 may begin to
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attenuate in an epidemic if the viral fitness set-point
during a new infection is frequently lower than the
fitness gain during disease. Virulent viruses that have
fast rates of killing, also have a reduced transmission
opportunity (R0). Thus, lethal viruses with lower
virulence may be selected in the human population
[14,15]. Although the ‘attenuation’ hypothesis has been
tested for HIV-1 in vitro [16], evolution and replicative
fitness of HIV-1 during the human epidemic has not
been studied, partly due to limited availability of
well-documented primary HIV-1 isolates from the early
epidemic (1980s).
Most research studies on HIV-1 replicative fitness have
established that drug resistant mutations reduce replica-
tion capacity [17,18] in the absence of antiretroviral drugs.
However, HIV-1 replicative fitness actually increases
during disease progression in treatment-naive patients
[11,12,19]. We have recently defined two parameters of
ex vivo fitness: ‘pathogenic fitness’ which measures the
relative HIV-1 replicative fitness in primary human
T cells, i.e., the major target cells during chronic HIV-1
infection; and ‘transmission fitness’ which measures the
efficiency of viral transfer from dendritic cells (i.e., crucial
targets during sexual HIV-1 transmission) to T cells [20–
24]. In this study we have compared the pathogenic and
transmission fitness of primary HIV-1 isolates from the
beginning of the epidemic (1986–1989) and more recent
viruses (2002–2003) from the same clinic in Antwerp,
Belgium. Direct head-to-head competitions of HIV-1
pairs (almost every combination) in peripheral blood
mononuclear cells (PBMC) or interstitial-type like
dendritic cells/T-cell cocultures suggest diminished
fitness of the more recent HIV-1 isolates. Recent findings
suggest that in the absence of drug resistance mutations,
reduced HIV-1 fitness is attributable to decreased
efficiency of host cell entry and maps to the HIV-1 env
gene. Evidence that the more recent HIV-1 isolates
were more sensitive to a CCR5-antagonist (TAK-779)
supports the hypothesis of reduced entry efficiency
[23,25].
Methods
Cells
PBMC, obtained from a HIV-seronegative buffy coat by
Ficoll-Hypaque density gradient centrifugation, were
stimulated with 2 mg/ml phytohemagglutinin (PHA) for
3 days and further maintained in RPMI 1640–2 mM
L-glutamine supplemented with 10% fetal bovine serum,
10 mM HEPES, 1 ng/ml interleukin-2 (IL-2), 100 U/ml
penicillin and 100 mg/ml streptomycin. Monocyte-
derived dendritic cells (MO-DC) were generated as
previously described [20]. Frozen lymphocyte fractions
were thawed on the day of infection and used to isolate
autologous CD4 T cells.
Patients and viruses
Twenty-four patients were selected from our cohort at the
Institute of Tropical Medicine in Antwerp, Belgium.
Twelve historical samples from untreated subjects in
1986–1989 were selected based on availability of primary
patient cells (PBMC) and plasma (continuously stored in
liquid nitrogen and at 808C, respectively). In addition,
we collected PBMC and plasma from 50 untreated
patients during 2002–2003 with available clinical/
immunological data and stored the samples accordingly
until use. Patient samples were further characterized for
genetic subtype (Env and Pro-RT), plasma bDNA viral
load and co-receptor tropism (as determined on
U87.CD4 cells expressing either CCR5 or CXCR4).
Subsequently, 12 viruses isolated in 2002–2003 were
matched with the historical samples for CD4 cell count,
co-receptor tropism and genetic subtype. Both groups of
drug-naive patients were not significantly different for
CD4 cell count (P ¼ 0.67, paired t test) and viral load
(P ¼ 0.40, paired t test). Overall, 16 HIV-1 isolates were
obtained from patients in early disease (i.e., CD4 cell
counts typically > 400/ml and non-syncytium inducing/
CCR5 tropic), while eight viruses were isolated from
patients in advanced disease (i.e., CD4 cell counts
typically < 200/ml and syncytium-inducing/CXCR4
tropic (Fig. 1a). Virus stocks were propagated from
primary patient cells in short-term cocultures with
HIV-seronegative donor PBMC. Subsequently, tissue
culture dose for 50% infectivity (TCID50) was calculated
using the Reed and Muench method [26]. Briefly,
all virus stocks were serially diluted in sixfold and then
added to activated PBMC. Following 12 days of incuba-
tion, supernatant was harvested and virus production
was measured using an in-house p24 antigen capture
ELISA [27]. Finally, 12 matched pairs of viruses were
used in dual virus competition assays to measure relative
fitness.
Growth competition assays
Nearly 750 competitions were performed with 24 HIV-1
primary isolates using PHA/IL-2 activated PBMC from
one donor (same donor as for TCID50 determination and
same blood draw) and in duplicate. A subset of
competitions (five virus pairs) was repeated in PBMC
from an additional donor to exclude host effects. Finally,
the same NSI/R5 isolates were used in dual infections
with MO-DC and autologous non-activated CD4
T cells. Cells were infected with two viruses at equal
multiplicity of infection (0.0005 infectious units/cell for
PBMC and 0.001 infectious units/cell for MO-DC),
uninfected cultures were used as HIV-negative controls
and monoinfected cell cultures of each virus corres-
pond to positive controls. As described elsewhere
[11,12,23,24], virus mixtures were incubated with
2  105 PBMC or 1  105 MO-DC at 378C in 5%
CO2 and washed three times with 1  phosphate-
buffered saline 24 h post-infection and then resuspended
in complete medium. Subsequently, 3  105 autologous
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Fig. 1. Virus characteristics (a) and phylogenetic analyses of historical (1986–1989) and more recent (2002–2003) HIV-1
subtype B isolates based on Env V1-V5 (b) and Pol (b) sequences. (a) Virus and patient characteristics of the HIV-1 isolates used
(1986–1989 viruses are in grey, 2002–2003 viruses are in black). Sequences were alignedwith Clustal X and thenmanually edited
with BioEdit using the amino acid sequence for misaligned insertions-deletions. All sequence gaps were stripped from the
alignment and phylogenetic trees were built with PAUP4.0b10. Neighbour-joining trees were constructed by using the HKY85
model of nucleotide substitution, with the transition/transversion ratio and alpha shape parameter for a gamma distribution
estimated directly from the data under maximum likelihood. The resulting model was used in a heuristic search with the subtree
pruning-regrafting algorithm for branch swapping to find the optimum tree. The significance of the branching order was estimated
by bootstrap resampling of 1000 replicates. Bootstrap values are displayed on significant branches (> 900; > 800, > 700).
Historical (1986–1989) and more recent isolates (2002–2003) analysed in this study are displayed on the trees in grey and black,
respectively (b and c). Average env genetic distances (d) were calculated according to the Kimura 2-parameter model usingMEGA
2.0 [44]. GenBank sequence accession numbers: DQ177188-DQ177211 (Env) and DQ177212-DQ177234 (Pol).
CD4 T cells were added to MO-DC cultures and fed with
complete medium twice weekly. Cell-free supernatant
was assayed for p24 antigen detection 4 and 7 days post-
infection. Two aliquots of supernatants and cells were
harvested at day 10 after infection and stored at808C for
subsequent analysis.
PCR
Proviral DNA was extracted from lysed PBMC using the
QIAamp DNA Blood kit (Qiagen, Qiagen Benelux b.v.,
Venlo, The Netherlands). HIV-1 DNA was PCR
amplified using a set of external primers (envB:
50–—AGAAAGAGCAGAAGACAGTGGCAATGA–—
30 and ED14: 50–—TCTTGCCTGGAGCTGTTTGA-
TGCCCCAGAC–—30) followed by nested amplification
(E80: 50–—CCAATTCCCATACATTATTGTG–—30
and E125: 50–—CAATTTCTGGGTCCCCTCCT-
GAGG–—30). Both the external and nested PCR
reaction was carried out in a 100-ml reaction mixture
under defined cycling conditions as reported earlier [11].
Heteroduplex tracking assay
Nested PCR products in env (C2V3) were analysed by
heteroduplex tracking assays (HTA) to determine the
amount of virus production in the dual infection/
competition experiments, as described previously
[11,12,23,24]. Radiolabelled DNA probes were ampli-
fied from regions of env by PCR using the same primer
sets described above, and one of the nested primers was
radiolabelled using T4 polynucleotide kinase and 2 mCi
[g-32P]ATP. We used the laboratory adapted HIV-1
strains IIIB and Ba-L and two subtype B primary isolates
(969-1 and 969-6) to generate radiolabelled DNA probes
and the same probes were used consistently to analyse all
competitions (subtype B and non-B), both in PBMC and
DC/CD4 T-cell cultures. Each competition was ana-
lysed, separately, with at least three different probes. From
previous analyses on diverse HIV types (1 and 2), groups
(O and M), HIV-1 M subtypes (A, B, C, D, 01_AE), we
know that probe binding and specificity does not differ
significantly among HIV-1 M subtypes [11,23,24].
Subsequently, radiolabelled PCR-amplified probes were
separated on 1% agarose gels and purified using the
QIAquick gel extraction kit (Qiagen). HTA reaction
mixtures containing DNA annealing buffer (100 mM
NaCl, 10 mM Tris–HCl pH 7.8, 2 mM EDTA), 10 ml
amplified DNA from the competition culture, and
0.1 pmol radioactive probe DNA were denatured at 958C
for 3 min followed by incubation at 378C for 5 min
and rapid transfer on wet ice to allow re-annealing.
DNA heteroduplexes were resolved on 5% TBE non-
denaturing polyacrylamide gels (Bio-Rad, Bio-Rad
Laboratories, Nazareth, Belgium) for 75 min at 200 V.
Gels were dried for 45 min at 808C, exposed and scanned
with a phosphor imager (Cyclone, PerkinElmer) and
analysed with OptiQuant (PerkinElmer, Zaventem,
Belgium).
Estimation of viral fitness
The final ratio of two viruses produced in a dual infection
was estimated by heteroduplex tracking analysis and
compared to the production in monoinfections. Pro-
duction of individual HIV isolates in a dual infection (fo)
was divided by the initial proportion in the inoculum (io).
This is referred to as relative fitness (W ¼ fo/io), while the
ratio of the relative fitness values of each HIV variant in
the competition is a measure of the fitness difference
(WD) or ratio between two HIV strains (WD ¼WM/
WL), with WM and WL corresponding to the relative
fitness of the more and less fit virus, respectively [11].
Sensitivity to TAK-779 and lamivudine
Sensitivity of NSI/R5 primary isolates was determined in
experiments with CCR5 co-receptor antagonist TAK-
779 and non-nucleoside reverse transcriptase (RT)
inhibitor lamivudine (3TC) (both obtained from NIH
AIDS Research & Reference Reagent Program).
U87.CD4.CCR5 cells were incubated with serial drug
dilutions (0.1 nM–10 000 nM for both TAK-779 and
3TC) 1 h prior to infection with HIV-1. Excess drug and
virus was washed away and medium containing drug was
replaced twice weekly. Drug was present before, during
and after infection. At day 10, aliquots of supernatant
were analysed for p24 antigen production.
Subtyping and sequence analyses
Envelope fragments (nucleotides 6594–7774,DQ177188-
DQ177211) were amplified by PCR and sequenced using
external primers envB, 50–—AGAAAGAGCAGAAG
ACAGTGGCAATGA–—30 and ED14, 50–—TCT
TGCCTGGAGCTGTTTGATGCCCCAGAC–—30
(1760 nt) and internal primers ED5, 50–—ATGGGAT
CAAAGCCTAAAGCCATGTG–—30 and ED12,
50–—AGTGCTTCCTGCTGCTCCCAAGAACCCA
AG–—30 (1255 nt). Pol fragments (nt 2280–3518,
DQ177212-DQ177234) corresponding to protease
amino acid 10 through RT amino acid 323 were PCR
amplified and sequenced using external primers PS1,
50–—TTTTTTAGGGAAAATTTGGCCTTC–—30
and RTA9, 50–—TAAATTTAGGAGTCTTTCCC-
CATA–—30 (1633 nt) and internal primers PS2, 50–—
TCCCTCAAATCACTCTTTGGCAAC–—30 and
RTA6subB, 50–—CCATTGGCCTTGCCCCTGCTT
CTG–—30 (1310 nt). Nucleotide sequencing was per-
formed using an ABI 3730 DNA sequencer at Davis
Sequencing Inc (Davis Sequencing, INC., Davis,
California, USA). For phylogenetic subtyping analyses,
nucleotide sequences were aligned using ClustalX and
then manually edited for codon alignment. Alignments
included a representative set of known subtype sequences
recommended by the Los Alamos HIV Sequence
Database. For env alignment, all sequence gaps were
removed (there were no gaps in the pol alignment),
neighbour-joining trees were generated using ClustalX
with 1000 bootstrap replicates and consensus trees were
displayed with TreeView [28].
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Results
Characterization of historical and recent HIV-1
isolates
Two sets of 12 HIV-1 isolates were propagated from
patient samples collected in 1986–1989 and in 2002–
2003. These patient samples were carefully matched based
on CD4 cell count and virus properties (viral load,
predicted co-receptor tropism and genetic subtype)
(Fig. 1a). Two-thirds of the HIV-1 isolates were NSI/
CCR5 tropic and obtained from patients in relatively
early disease (i.e., CD4 cells typically > 400 ml), while
one-third were SI/CXCR4 tropic and isolated from
patients in advanced disease (i.e., CD4 cells typically
< 200 ml). Infection of U87.CD4.CCR5 or U87.CD4.
CXCR4 cells was the basis for determining co-receptor
usage. Fifteen of 24 viruses were classified as subtype B
based on DNA sequencing and phylogenetic analyses of
the env gp120 coding region and the protease-RT region
of pol. The other nine HIV-1 isolates were of different
subtypes (A1, G, F1) and circulating recombinant forms
(CRF01_AE, CRF02_AG, CRF05_DF, CRF14_BG).
Phylogenetic trees were also constructed to confirm
genetic intermixing of both historical and recent subtype
B viruses in both the pol and env genes (Fig. 1b and c).
DNA distance matrices indicated that recent subtype B
HIV-1 isolates were slightly more heterogeneous in both
pol and env genes (Fig. 1d). However, genetic distances
between recent and historical HIV-1 isolates were not
significantly different. Finally, a PSSM score for all of
the V3 sequences of each subtype B isolate confirmed
the tropism determined by the U87.CD4.CCR5
(or CXCR4) infection experiments (see online supple-
mentary data) [29].
Comparing the replicative fitness of historical
and recent HIV-1 isolates in PBMC
HIV-1 isolates of 24 untreated patients were used in full
pair wise, head-to-head competitions using activated
human PBMC as target cells. Upon peak virus
production, viral DNA was PCR amplified and used
in a modified HTA to measure dual virus production.
The estimated frequency of recombination between
HIV-1 isolates in the dual infection competition assay is
0.1%/1000 base pairs, well below the limit of HTA
detection [11]. HTA involves denaturation and annealing
of PCR-amplified HIV-1 env products from the dual
infection with a radiolabelled env probe from a different
HIV-1 strain. Heteroduplex bands representing both
HIV-1 isolates in the dual infection migrate to distinct
positions on a non-denaturing polyacrylamide gel, which
is then quantified using phosphorimaging. At least two
probes were used for each competition resulting in
identical fitness values. We have previously performed a
series of HTA controls for PCR amplification, probe
annealing, and quantification [11,12,23,24,30,31]. This
technique can be used with any two HIV isolates without
specific sequence information and was even more reliable,
quantitative, and sensitive (up to 500-fold differences in
fitness) than real-time PCR [32].
The majority of competitions between historical and
recent HIV-1 isolates from patients attending the same
clinic in Antwerp showed that recent isolates were less fit
than historical viruses (Fig. 2, Fig. 3). Historical HIV-1
out-competed recent viruses in 176 out of 238
competitions (74%) and the mean relative inter-group
replicative fitness (W) (i.e., direct competitions between
isolates from both groups) was 1.395 and 0.545,
respectively (P < 0.001, t test). Direct competitions
between isolates within the same group (i.e., intra-group
fitness) showed no apparent fitness differences (i.e.,
W ﬃ 1). The relative replicative fitness value for the
1986–1989 viruses was 0.959 (P ¼ 0.85) and W2002–
2003 ¼ 0.932 (P ¼ 0.96) for the recent HIV-1 (Fig. 3).
Twelve competitions within the complete set involved
pairs of historical and recent isolates that were derived
from patient samples with matched CD4 cell counts, viral
load, HIV-1 co-receptor tropism, and virus subtype.
Historical patient viruses out competed their 2002–2003
counterparts in nine out of twelve of these competitions
(Fig. 2).
To exclude possible influence of divergent HIV-1
subtypes, we re-analysed the data for the 15 subtype B
isolates and confirmed that subtype B viruses of the 1980s
were significantly more fit than those isolated in 2002–
2003 (W1986–1989 ¼ 1.361 and W2002–2003 ¼ 0.565,
P ¼ 0.014, t test) (Fig. 3). A subset of competitions
between viruses of the two groups was repeated in PBMC
of another donor, to exclude possible host effects. Total
HIV-1 production was higher in the PBMC of one donor
but the relative production of each virus (i.e., relative
replicative fitness) in the dual infection was similar with
both donors (as observed in five independent studies)
[11,12,23,24,30].
A factor that may have contributed to this possible
attenuation is the advent of antiretroviral therapy (ART)
in the late 1980s. Although none of these samples were
obtained from patients with ongoing treatment, we still
screened for drug resistance mutations by sequencing the
protease-RT coding regions of pol (see online supple-
mentary data). Surprisingly, the historical VI 321 was
the only patient isolate to harbour a single drug resistance
mutation, i.e., K70R encoding resistance to zidovudine
[17]. The VI 321 HIV-1 isolate was actually more fit
that the vast majority of the recent viruses (Fig. 2k,
Fig. 3b).
In a previous study, we showed that R5 viruses of higher
fitness appeared to be less sensitive to entry inhibitors such
as PSC-RANTES, TAK-779, and T-20 [30]. To confirm
and extend this observation, we measured the sensitivity
of the historical and recent R5 HIV-1 isolates to the RT
inhibitor, 3TC and the CCR5 antagonist, TAK-779. In
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general, the 1986–1989 viruses appeared less sensitive to
TAK-779 and 3TC than did the 2002–2003 viruses, but
this trend was not statistically significant (Fig. 4a). Viruses
characterized as being more fit (mean W > 1) were also
less sensitive to TAK-779 and 3TC than the less fit (mean
W < 1) (Fig. 4b).
Historical HIV-1 isolates may have higher
‘transmission fitness’
Animal models of sexual transmission suggest that
dendritic cells may be initial targets of primary HIV-1
infection [21,22]. ‘Transmission fitness’ may be related to
the efficiency of virus transfer from dendritic cells to T
cells, whereas the replicative fitness in T cells may be
more related to ‘pathogenic fitness’ [24]. Based on our
observations in PBMC, a subset of the matched historical
and recent viruses was competed in autologous dendritic
cell/CD4 T-cell co-cultures.
We observed that transfer from dendritic cells to T cells
was more efficient for the historical isolates. The two
recent HIV-1 isolates (VI 2627 and VI 2681) that were
more fit than their historical counterparts (VI 276 and VI
318) in PBMC, were also more fit in dendritic cell/CD4
T-cell competitions. In one of these selected pairs where
the recent virus out-competed the historical strain (VI
342 vs. VI 2622) in PBMC, dominance of the recent virus
(VI 2622) was not absolute since VI 342 had increased
‘transmission fitness’ in the MO-DC/CD4 T-cell cultures
(Fig. 5).
Discussion
This study provides the first evidence suggesting that
present-day HIV-1 patient isolates have reduced replica-
tive fitness as compared to viruses isolated 15 years earlier
in the Belgian epidemic. Reduced replicative fitness was
shown both in activated human T cells and in autologous
co-cultures of interstitial-like dendritic cells and CD4 T
cells (i.e., to model HIV-1 transfer). Finally, we also show
that a subset of the same drug-naive 2002–2003 isolates
are more sensitive to inhibition by a CCR5 co-receptor
antagonist (TAK-779) and a RT inhibitor (3TC). Our
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Fig. 2. Comparing the relative replicative fitness difference
(WD) of historical and recent HIV-1 patient isolates in direct
competition.Historical isolates (VI 75, VI 339, VI 180, VI 342,
VI 178, VI 48, VI 276, VI 318, VI 334, VI 218, VI 321, and VI
64) were used to compete against each of the more recent
isolates (VI 2617, VI 2621, VI 2678, VI 2626, VI 2673, VI
2622, VI 2641, VI 2642, VI 2627, VI 2681, and VI 2687) with
equal multiplicity of infection for each isolate. Each isolate
name is followed by the coreceptor tropism and CD4
cell count (e.g., VI 75-R5-120: virus isolate 75 uses CCR5
as coreceptor for entry and has a CD4 cell count of
Fig. 2. (continued)
120 ml). Historical and recent HIV-1 strains were further
subdivided according to coreceptor tropism: R5 (panel A-
H), R5X4 (panel I and J), and X4 (panel K and L). All of the X4
versus X4 competitions are grouped in panels K and L, the X4
vs. R5X4 are in panels I, J, K, and L, and R5X4 versus R5 are in
panels I and J. Blue bars represent competitions between
historical and recent isolates that were matched for CD4 cell
count, coreceptor tropism, bDNA viral load, and genetic
subtype. (nd, not done).
observation on decreased sensitivity to TAK-779 is in line
with earlier reports suggesting that differences in fitness
may be related to entry efficiency [23,25,30].
Myxoma virus infections in rabbits may be the best
documented case of virus-host adaptation and shows that
viruses do not per se evolve toward greater pathogenic
potential. Introduction of myxoma in the susceptible
rabbit population of Australia in 1950 quickly resulted in
the outgrowth of attenuated strains [33]. Although
difficult to study, epidemio-mathematical models of
host-pathogen interaction have suggested that many
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Fig. 3. Mean competitive advantage of historical isolates over recent isolates. (a) Mean replicative fitness of the complete set of
dual virus competitions (n ¼ 238 competitions) is shown in (a) 1986–1989 isolates and (b) 2002–2003 isolates, while results on
subtype B isolates only (n ¼ 92 competitions) are shown in (c) 1986–1989 and (d) 2002–2003. Both groups of isolates are not
significantly different for CD4 cell count (P ¼ 0.67 and 0.66, paired t test) and viral load (P ¼ 0.40 and 0.99, paired t test).
However, the mean relative fitness between 1986–1989 and 2002–2003 HIV-1 viruses was significantly different in the complete
set of competitions involving all 24 viruses (W1986–1989 ¼ 1.395, W2002–2003 ¼ 0.545, P < 0.001) and in the subset of subtype B
isolates (W1986–1989 ¼ 1.361, W2002–2003 ¼ 0.565, P ¼ 0.014). (b) Mean replicative fitness values for inter-group versus intra-
group competitions in PBMC. The mean intra-group replicative fitness for 1986–1989 HIV-1 isolates and 2002–2003 HIV-1
isolates is W ¼ 0.959 and W ¼ 0.932, respectively. However, full pair-wise inter-group replicative fitness comparison revealed
that historical isolates are significantly more fit than isolates from 2002–2003. The average inter/intra replicative fitness for each
group is represented by the grey and black triangle.
lethal viruses and bacteria have evolved to low virulence
or even to a symbiotic existence with the host [14]. We
recently established a fitness order for most human
immunodeficiency lentiviruses: HIV-1 group M > HIV-
2 > HIV-1 group O [24]. Interestingly, HIV-2 was of
high prevalence in West Africa during the late 1980s and
early 1990s but has precipitously diminished over the last
10 years due to poor transmission and low virulence [3].
Although there may be many host genetic factors
affecting HIV-1 virulence, the most striking examples
are protection due to the deletion in a CCR5 allele [34]
and slower disease progression due to multiple CCL3L1
(MIP-1 aP) gene copies [35]. However, unlike virus
attenuation, selection in human hosts leading to reduced
virulence, requires a high HIV-1 prevalence, high
transmission rates, frequent opportunity for transmission
and a much longer time.
The mechanisms responsible for a possible HIV-1
attenuation are complex and multifaceted but are likely
to involve directional evolution towards increased survival
and transmission at the cost of lowering virulence. Over
the course of nearly three decades HIV-1 has probably
evolved and lost replicative fitness to avoid cytotoxic T-
lymphocytes (CTL) [36,37] and humoral immune
responses as well as ART interventions [38]. Recent
studies provide evidence for the adaptation of HIV-1 to
HLA-restricted immune responses at the population level
[39]. As HIV-1 sweeps through the human population,
the human immune system leaves behind host-specific
footprints in the viral genome. However, Bonhoeffer et al.
[40] described positive epistasis in the HIV-1 subtype B
epidemic, which implies that mutation and recombina-
tion may benefit for the virus in the human population.
Unfortunately, these comparisons of genetic evolution
and replicative fitness have been limited to the HIV-1
protease-RT regions derived from patients receiving
ART. Our observations are not based on one specific
genomic region, but on the complete virus as it is
circulating in the drug-naive human population. How-
ever a key question remains: does shared CTL responses/
HLA types in specific human populations or various host
genetic polymorphisms affect temporal virus evolution
and as a consequence, virulence?
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Fig. 4. Sensitivity to inhibition by 3TC and TAK-779. Inhi-
bition experiments with TAK-779 (a CCR5 co-receptor
antagonist) and 3TC (a non-nucleoside reverse transcriptase
inhibitor) were performed on a representative group of
primary HIV-1 isolates. As described in materials and
methods, U87.CD4.CCR5 cells were incubated with serial
dilutions of both drugs (0.1 nM – 10 000 nM) for 1 h and in
sixfold replicates. Virus (0.001 infectious units/cell) was
added to pre-treated cells and cultures were incubated for
24 h at 37 8C and 5%CO2. Virus and drug were washed away
and cultures were fed twice weekly with drug-containing
medium. At 10 day post-infection, aliquots of supernatant
were assayed for p24 antigen concentration. A representative
set of eight primary isolates (i.e., four isolates from 1986–
1989 and four from 2002–2003), matched for CD4 cell count
and co-receptor tropism, was assayed for sensitivity to TAK-
779 and 3TC. The 50% inhibitory concentration (IC50) (nM)
obtained for each isolate is shown (diamonds for 1986–1989
isolates and boxes for 2002–2003 isolates). A line displays the
Fig. 4. (continued)
average IC50 value (nM) for each group of viruses. Differential
sensitivities of historical and recent viruses are presented in
(a), while (b) shows differential sensitivities of the more fit and
the less fit viruses. The historical viruses (a) appear to have
higher IC50 values (nM), meaning that they are less susceptible
to inhibition by both TAK-779 and 3TC. These results suggest
that the viruses from 2002–2003, which display poor replica-
tion capacity in comparison with isolates from 1986–1989,
are more sensitive to inhibition by TAK-779 and 3TC. Sim-
ilarly, high fitness viruses (b) appear less susceptible to inhi-
bition by TAK-779 and 3TC.
Several studies on intra-patient HIV-1 replicative fitness
evolution have provided evidence that the replicative
fitness of HIV-1 tends to progressively increase through
the course of infection in the absence of ART [11,12,19].
It is not unlikely that fitness gains that correlate with
increasing intra-patient HIV-1 diversity may be host
limited due to significant bottlenecking that results from
HIV-1 transmission. Consecutive genetic bottlenecks
with each transmission event may reset the fitness set
point for each new infecting virus. If the reduction in
replicative fitness upon transmission is on average greater
than the replicative fitness increase within an infected
individual prior to new transmission, HIV-1 could
attenuate in the human population over time. It is well
known that successive transmission events of RNA
viruses may cause deleterious genetic bottlenecks that
result in profound fitness losses (i.e., Muller’s ratchet)
[41–43]. As described above, this process of HIV-1
attenuation through genetic bottlenecks at transmission,
could only accelerate by ongoing adaptation to common
HLA types in the population.
In conclusion, we have studied the evolution of HIV-1
replicative fitness and drug-inhibition efficiency of HIV-1
isolates from untreated patients and show the first
experimental evidence suggestive for HIV-1 attenuation
over time. Although our observation is based on a limited
number of HIV-1 isolates and needs to be confirmed in
independent studies, we believe that these findings
provide a new paradigm and are crucial in our thinking on
HIV-1 evolution in the epidemic.
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